Skip to main content

Weight Watchers Announces Leadership Transition and Board Updates 

Office of the CEO Established to Oversee Business Operations  Board Forms Transition Committee and Commences CEO Search NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced leadership and governance changes, including the establishment of an Office of the CEO and the formation of a new Transition Committee of the Board of Directors (“the Board”). These actions follow Tara Comonte’s departure from the Company, effective March 31, 2026.  The Company’s Board of Directors has initiated a comprehensive search for a permanent successor with the support of a leading executive search firm. During the transition period, the Office of the CEO will oversee business operations and execution of the Company’s...

Continue reading

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the Company’s common stock to five newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of March 31, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.68 per share, which is equal to the closing price of the Company’s common stock on the Effective Date....

Continue reading

Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans

HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) — Impact BioMedical Inc. (NYSE American: IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from Grassi & Co., CPAs, P.C. that contains a “going concern” qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company’s financial statements for the year ended December 31, 2025. Again, this announcement does not represent any change or amendment to the Company’s financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2025. Separately, Impact Biomedical...

Continue reading

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technology Results from ongoing Phase 1/2 study in patients with FTD-GRN expected by the end of 2026SOUTH SAN FRANCISCO, Calif., April 03, 2026 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it has received notification from Takeda of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN). The decision was driven by strategic considerations and is not related to efficacy or safety data. DNL593 is an investigational progranulin replacement therapy utilizing Denali’s Protein TransportVehicle™ (PTV) to deliver progranulin across the blood-brain barrier to the brain for the...

Continue reading

Former Sen. Sam Nunn Visits Ingalls Shipbuilding for Update on His Namesake Destroyer

PASCAGOULA, Miss., April 03, 2026 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division recently welcomed former U.S. Sen. Sam Nunn, his wife, Colleen Nunn, and their daughter and ship sponsor Michelle Nunn, for a visit to the shipyard. The visit included a construction update and tour of the future USS Sam Nunn (DDG 133), a Flight III Arleigh Burke-class destroyer named in honor of the senator, and marked their return to Ingalls following the ship’s keel authentication ceremony. “It was an honor to welcome Sen. Nunn and Michelle Nunn to Ingalls to see first-hand the progress taking place on DDG 133 and to highlight the ship’s advancing construction path toward launch,” Ingalls Shipbuilding President Brian Blanchette said. “Our shipbuilders take tremendous pride in building a ship that will carry Sen. Nunn’s name and...

Continue reading

Proposed appointment to the Board of Directors at the Annual General Meeting on May 21st, 2026: Thierry Fournier candidate director – Appointed censor with immediate effect

Proposed appointment to the Board of Directors at the Annual General Meeting on May 21st, 2026: Thierry Fournier candidate director – Appointed censor with immediate effect   _PRESS RELEASE_ Paris, April 3rd, 2026 – The Nexans Board of Directors has appointed Thierry Fournier as censor with a view to proposing his appointment as member of the Board of Directors to the shareholders’ general meeting to be held on May 21st, 2026. As censor, Thierry Fournier will attend Board of Directors meetings with a consultative role, and the Board will benefit immediately from his extensive experience and expertise. The Internal Regulations of the Board will be applicable to him in full. Thierry Fournier has served as Chief Executive Officer of Roquette since 2025. Before joining Roquette  he was Senior Vice President and CEO for Southern Europe, the...

Continue reading

Ponce Bank Ranked Among Top 50 Best-Performing U.S. Community Banks by S&P Global Market Intelligence

BRONX, N.Y., April 03, 2026 (GLOBE NEWSWIRE) — Ponce Bank, National Association, the banking subsidiary of Ponce Financial Group, Inc., has been recognized by S&P Global Market Intelligence as one of the Top 50 Best-Performing U.S. Community Banks of 2025 in the $3 billion to $10 billion asset category, ranking #40 nationally. This recognition underscores the Bank’s strong financial performance while reaffirming its longstanding commitment to community impact and inclusive growth. S&P Global Market Intelligence’s annual rankings evaluate financial institutions based on key performance indicators including returns, growth, funding, and balance sheet strength, with a particular emphasis on risk profile and long-term stability. Ponce Bank’s placement reflects a balanced approach to performance—delivering solid financial results...

Continue reading

BIC: Disclosure Of Trading In Own Shares For March 2026

Disclosure Of Trading In Own Shares For March 2026 Clichy, France – April 03, 2026 In compliance with general regulation on share buy-backs, Société BIC declares below the transactions made on its own shares for March 2026:Date Number of shares Average weighted price in € Amount in €03/03/2026 5,000 52.5000 262,500.0003/03/2026 2,179 52.6930 114,818.0503/03/2026 10,936 52.6930 576,250.6504/03/2026 3,411 52.6398 179,554.2006/03/2026 278 54.0000 15,012.0009/03/2026 12,515 53.2291 666,162.1910/03/2026 2,058 53.9986 111,129.1211/03/2026 7,909 53.9611 426,778.3412/03/2026 6,165 53.9566 332,642.4416/03/2026 6,734 53.9170 363,077.2017/03/2026 6,683 53.7643 359,306.8817/03/2026 3,317 53.7643 178,336.2218/03/2026 7,640 52.9334 404,411.1818/03/2026 139 52.9334 7,357.7419/03/2026 46,553 51.9000 2,416,100.7031/03/2026 45,519 53.7000 2,444,370.30TOTAL 167,036 53.0293 8,857,807.20ContactsBrice...

Continue reading

Draft resolutions of the Annual General Meeting of Akcinė prekybos bendrovė “APRANGA” shareholders to be held on 30th April 2026

Draft agenda and draft resolutions for the Annual General Meeting of Akcinė prekybos bendrovė “APRANGA” (hereinafter the “Company”) shareholders to be held on 30th April 2026 proposed by the Board of the Company:Auditor’s reports on the Company’s financial statements, management report and sustainability reporting assurance.Draft resolution: No decision is required on this agenda item. The information has been noted.Consolidated management report on the activities of the Company in 2025.Draft resolution: Taken for the information consolidated management report of the Company for the year 2025, prepared by the Company, assessed by the auditors and approved by the Board.Approval of the Remuneration Report of the Company (included in the Company’s Consolidated management report)Draft resolution: Approve the Remuneration Report...

Continue reading

Dassault Aviation: Total number of shares and voting rights – 31 03 26

DASSAULT AVIATION French corporation (société anonyme) with a share capital of 62,170,196.80 euros Headquarters: 78, quai Marcel Dassault 92210 SAINT-CLOUD 712 042 456 RCS Nanterre Information concerning the total number of voting rights and shares as per article L. 233-8 II of the French Commercial Code (Code de commerce) and article 223-16 of the General Regulations (Règlement Général) of the French Market Authority (Autorité des Marchés Financiers)DateTotal number of sharesTotal number of voting rights03/31/2026 77,712,746Theoretical voting rights: 129,926,031 Exercisable voting rights: 129,779,833AttachmentTotal number of shares and voting rights – 31 03 26

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.